🟢 Eli Lilly is trading 3.33% up today after Q2 revenue and EPS beat, guidance raised

Eli Lilly is trading 3.33% up now at $1190.00 after its August 5, 2026 earnings report exceeded expectations.

• Second-quarter revenue was $22.97 billion and adjusted EPS was $8.38; management raised 2026 revenue guidance to $85 billion–$87 billion.
• The outlook reflects strong Mounjaro and Zepbound demand; Foundayo generated $98 million, slightly below estimates.
• The earnings-driven rally follows a 4.86% gain on August 5, 2026, with healthcare-sector strength providing additional support for continued buying.